Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience

Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience

Abstract Background Systemic juvenile idiopathic arthritis (sJIA) is a severe form of juvenile arthritis that is characterized by chronic joint inflammation and systemic symptoms such as fever, rash, and organ involvement. Anti-IL-6 receptor monoclonal antibody tocilizumab is an effective treatment....

Full description

Bibliographic Details
Main Authors: Lingzhi Qiu, Le Ma, Yifan Xie, Jing Jin, Yuting Pan, Shumin Li, Zhidan Fan, Haiguo Yu
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Canakinumab
Interleukin-1
Systemic juvenile idiopathic arthritis
Online Access:https://doi.org/10.1186/s12969-024-00974-4

Similar Items

Similar Items